S.T.E.P.S.™: A comprehensive program for controlling and monitoring access to thalidomide*
References (17)
- et al.
The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital abnormalities
NEJM.
(1962) Thalidomide in autoimmune conditions
Exp Opin Invest Drugs.
(1996)Thalidomide in the treatment of lepra reactions
Clin Pharmacol Ther.
(1965)- et al.
Results of a doubleblind study on the influence of thalidomide on the lepra reaction
Int J Lepr.
(1969) - et al.
WHO co-ordinated short-term doubleblind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients
Bull WHO.
(1971) - et al.
Thalidomide revisited: Pharmacology and clinical applications
Exp Opin Invest Drugs.
(1998)
There are more references available in the full text version of this article.
Cited by (216)
Thalidomide, the story goes on
2023, Anales de PediatriaThe History of Dermatology and Dermatologists at the US Food and Drug Administration
2022, Dermatologic ClinicsSafety of medicines and vaccines – building next generation capability
2021, Trends in Pharmacological SciencesThalidomide use in the management of oromucosal disease: A 10-year review of safety and efficacy in 12 patients
2020, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- *
Trademark: THALOMID™ (Celgene Corporation, Warren, New Jersey).
Copyright © 1999 Published by Elsevier Inc.